Genzyme Seeks Toss Of Investors' Insider Trading Suit

Law360, New York (February 1, 2011, 7:28 PM EST) -- Genzyme Corp. has asked a federal judge to dismiss a shareholder suit that accuses company executives of misleading the U.S. Food and Drug Administration and selling $117 million worth of stock based on nonpublic information.

The biotech giant said that its board of directors has already responded to the shareholders’ allegations and found no evidence of wrongdoing by the defendants in a motion filed on Monday in the U.S. District Court for the District of Massachusetts.

The shareholders claim that the defendants — Genzyme CEO Henri...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re GENZYME CORP. DERIVATIVE LITIGATION


Case Number

1:09-cv-12170

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

George A. OToole, Jr

Date Filed

December 22, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.